Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.68 |
| ▸ | CDK4 | P11802 | 4/20 | 0.57 |
| ▸ | CDK2 | P24941 | 4/20 | 0.57 |
| ▸ | CCND3 | P30281 | 3/20 | 0.56 |
| ▸ | CLK1 | P49759 | 1/20 | 0.56 |
| ▸ | CLK2 | P49760 | 1/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.56 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.56 |
| ▸ | BRAF | P15056 | 1/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.55 |
| ▸ | PLK1 | P53350 | 1/20 | 0.54 |
| ▸ | MTOR | P42345 | 2/20 | 0.52 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.52 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | PIM1 | P11309 | 2/20 | 0.51 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2956376 | 0.90 | PLK1 (0.68) | GSK3BCDK4CDK2CCND3BRAF | |
| SCHEMBL2955416 | 0.88 | GSK3B (0.57) | GSK3BCDK4CDK2CCND3CLK1 | |
| SCHEMBL2944816 | 0.85 | CLK1 (0.60) | GSK3BCDK2CLK1CLK2DYRK1A | |
| SCHEMBL4479938 | 0.82 | GSK3B (1.00) | GSK3BCDK4CDK2 | |
| SCHEMBL4738297 | 0.81 | PLK1 (0.68) | GSK3BCDK2CLK1CLK2DYRK1A | |
| SCHEMBL21074032 | 0.81 | BRAF (0.64) | GSK3BCDK4CDK2BRAFMAPK14 | |
| SCHEMBL4482281 | 0.81 | GSK3B (1.00) | GSK3BCDK2 | |
| SCHEMBL19966865 | 0.81 | BRAF (0.68) | GSK3BCDK4CCND3BRAFMAPK14 | |
| SCHEMBL4737084 | 0.81 | SYK (0.62) | GSK3BCDK4CDK2CLK1CLK2 | |
| SCHEMBL4892529 | 0.81 | CLK1 (0.65) | GSK3BCDK4CDK2CCND3CLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759357-B2 | Phenylpyrimidine amines as IgE inhibitors | NOVARTIS AG (CH) | 2010-07-20 | — | — | US | disclosed |
| US-20080279829-A1 | Phenyl-(4-Phenyl-Pyrimidin-2-Yl)-Amines For Enhancing Immunotolerance | WOISETSCHLAEGER MAXIMILIAN | 2008-11-13 | — | — | US | disclosed |
| US-20080279829-A1 | Phenyl-(4-Phenyl-Pyrimidin-2-Yl)-Amines For Enhancing Immunotolerance | WOISETSCHLAEGER MAXIMILIAN | 2008-11-13 | — | — | US | disclosed |
| EP-1474146-B1 | PHENYLPYRIMIDINE AMINES AS IGE INHIBITORS | NOVARTIS AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| EP-1933839-A1 | PHENYL-(4-PHENYL-PYRIMIDIN-2-YL)-AMINES FOR ENHANCING IMMUNOTOLERANCE | Novartis AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| US-20070281956-A1 | Phenylpyrimidine amines as IgE inhibitors | NOVARTIS AG (CH) | 2007-12-06 | — | — | US | disclosed |
| WO-2007039216-A1 | PHENYL-(4-PHENYL-PYRIMIDIN-2-YL)-AMINES FOR ENHANCING IMMUNOTOLERANCE | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039216-A1 | PHENYL-(4-PHENYL-PYRIMIDIN-2-YL)-AMINES FOR ENHANCING IMMUNOTOLERANCE | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| US-20050119255-A1 | Phenylpyrimidine amines as ige inhibitors | BULUSU MURTY (AT) | 2005-06-02 | — | — | US | disclosed |
| EP-1474146-A1 | PHENYLPYRIMIDINE AMINES AS IGE INHIBITORS | Novartis AG (CH) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003063871-A1 | PHENYLPYRIMIDINE AMINES AS IGE INHIBITORS | NOVARTIS AG (CH) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080279829-A1 | Phenyl-(4-Phenyl-Pyrimidin-2-Yl)-Amines For Enhancing Immunotolerance | IFNG, IL2, LY96 | GSK3B 4583/4885CDK4 2063/4885CDK2 2993/4885 |
| US-20070281956-A1 | Phenylpyrimidine amines as IgE inhibitors | FCER2, SELP, FCGR2A | GSK3B 2749/4885CDK4 692/4885CDK2 678/4885 |
| US-20050119255-A1 | Phenylpyrimidine amines as ige inhibitors | FCER2, SELP, FCGR2A | GSK3B 2749/4885CDK4 692/4885CDK2 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.